Quest Diagnostics Inc (DGX) · Oct 22, 2026 · Earnings
Beat — Adjusted EPS $3.00 vs ~$2.87 consensus; revenue $3.097B vs ~$3.05B
Quest Diagnostics earnings beat Q3 expectations, while higher volume and automation support a raised 2026 revenue and EPS outlook.
Quest Diagnostics is a scaled U.S. laboratory operator expanding through physician, hospital, consumer, advanced-diagnostics, acquisition, automation, and AI initiatives. Its standing growth plan already called for above-market expansion in those channels, so this filing matters because it shows that strategy converting into faster volume and a higher 2026 outlook.
The quarter cleared expectations on both major measures. Adjusted diluted EPS was $3.00 versus a published consensus of roughly $2.87, while revenue was $3.097 billion versus approximately $3.05 billion; that is a genuine earnings beat, not merely year-over-year growth. The company said it delivered 10% revenue growth and more than 15% adjusted EPS growth.
| Metric | Q3 2026 | Q3 2025 / prior guidance | Read |
|---|---|---|---|
| Revenue | $3.097B | $2.816B; +10.0% | Beat published consensus of ~$3.05B |
| Adjusted diluted EPS | $3.00 | $2.60; +15.4% | Beat published consensus of ~$2.87 |
| Requisition volume | +14.5% | — | Main growth engine |
| Revenue per requisition | -4.2% | -2.8% prior-year comparison | Pricing/mix remains a drag |
| Adjusted operating margin | 16.7% | 16.3% | Expanded 0.4 percentage points |
| Nine-month operating cash flow | $1.486B | $1.421B; +4.6% | Growth trails earnings |
| 2026 adjusted EPS guidance | $11.25-$11.35 | $11.05-$11.25 | Raised |
| 2026 revenue guidance | $12.065B-$12.105B | $11.95B-$12.05B | Raised |
The strongest underlying signal is volume, not pricing. Requisition volume rose 14.5%, including 14.4% organic growth, while revenue per requisition fell 4.2%. That means demand and channel access are expanding materially, but Quest is accepting lower revenue per test or facing mix/pricing pressure; the quarter still produced modest adjusted-margin expansion because productivity gains and scale more than offset that drag.
Management raised the full-year bar, making the beat more consequential. The updated ranges lift the midpoint of adjusted EPS guidance by about $0.15 and the revenue midpoint by about $85 million, while expected operating cash flow rises to approximately $1.90 billion from $1.80 billion. The company explicitly tied the increase to current performance. 〔0〕
The strategic additions broaden the growth funnel but are not yet financial drivers. Quest finalized an agreement to acquire select Northeastern outreach-lab assets, added direct test-panel purchasing through Apple Health, and expanded its Alzheimer’s blood-testing menu. These initiatives reinforce its hospital, consumer, and advanced-diagnostics strategy, but the filing provides no deal price or quantified contribution, so their near-term earnings effect is not yet measurable. 〔1〕
Bottom line: This is a clean beat with a real upward revision to the 2026 outlook. The business is growing primarily through unusually strong test volume, while pricing pressure remains the main offset; overall, the filing meaningfully advances Quest’s growth story rather than merely confirming it.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!